Company
8 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
JUL 28, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for linezolid labeling change; this is a regulatory action, not a clinical trial, and does not report efficacy or safety data.
FDA approval of an generic intravenous edaravone formulation; represents regulatory authorization but does not report clinical trial outcomes or comparative efficacy data.
JUL 8, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of dexmedetomidine hydrochloride labeling; no clinical trial data or efficacy evidence reported in this regulatory action record.
FDA approval of selenious acid intravenous solution; this is a regulatory action, not a clinical efficacy study, and does not report trial outcomes or comparative benefit.
FDA approval of a generic tofacitinib formulation; this is a regulatory action record documenting market authorization, not a clinical trial or efficacy study.
JUN 2, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
This is an FDA supplemental approval action for labeling of arsenic trioxide; it documents a regulatory decision, not clinical trial evidence or efficacy data.
MAY 14, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of labeling for lurasidone hydrochloride formulations; this is a regulatory action record, not a clinical trial, and contains no efficacy or safety outcome data.
APR 29, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of labeling changes for carbamazepine extended-release tablets; does not report clinical trial outcomes or efficacy data.